VPUbio Limited was established in 2024 to leverage the 20 years of expertise in viral pseudotyping from Founder and Director Professor Nigel Temperton. VPUbio will act as an end-to-end consultancy for the establishment of pseudotype virus-based serological pipelines and reagents within stakeholder laboratories across many sectors. The R&D focus of VPUbio is on the exploitation of Retro, Lenti and VSV vectors as serological antigens for high-throughput, sensitive neutralisation assays for emerging viruses. VPUbio has a current enhanced focus on influenza and the coronaviruses, but also encompasses many viruses of global concern for human and animal health listed in the June 2024 WHO Pathogens Prioritization list.